AMZNprintsminutestrendsdividendsdrawdownsP/E 28.4macronarrativesvolatilitybuybackssentiment+0.8%marginsMSFTPMI 52.1momentumdividendsflowsPMI 52.1digeststhreadsvolatilityearnings callsvolumesβ 1.24breakoutsnewsflow2s10sliquidityheadlines−1.2%breakoutsnoiseGOOGLbuybacksrevisionstrendsPMI 52.1briefstickersnoiseGDPsentimentchattertranscriptsGOOGLsentimentvolatilitybuybacksMSFTwhispersMETAsessionsyield curves13FfuturesdowngradesPMI 52.1headlinesthe tapeflowsdowngradesfutures+0.8%earnings callstranscriptsclosesgammacatalystsrevisionsvolatilitysentimentchatter+2.41%earnings callssentimentfilingstrends10y 4.21%cyclesbuybackswiresspx 0dtewhisperstickersQ3trendsnewsflowearnings callsWTI 78.2sentimentnoisethreadsrumorsnarrativesFOMCconsensusestimatesmomentumYoY +18%tickersmomentumprintsβ 1.24revisions

momentumheadlines52w hipositioning2s10sfilingstrendsprintstrendsmacrocyclesnoise2s10smacroQ3narrativesheadlinesflowscyclesnarrativesspreadstranscriptsdowngradesupgradeswhisperswhispersminutesthe tapeNDXfuturesminutesyield curves52w hithe tapeFOMCcatalystsbriefsthe tapeNVDAguidancetrends52w hidrawdowns2s10swhispersmomentumdrawdownsbuybacks

PCEliquiditysentimentbreakoutsdowngradesP/E 28.4threadsAAPLSPXvolatilityNDXflowscyclesliquidityestimatesEPS 4.12

XENE · NASDAQ · Biotechnology

Xenon Pharmaceuticals (XENE)

Develops azetukalner and ion-channel medicines for epilepsy, depression, and pain.

$39.18

After hours+0.10 (+0.27%)

At close$39.08(+0.22%)

In millions of USD, except per-share figures

In millions	Q3 FY23Sep 2023	Q4 FY23Dec 2023	Q1 FY24Mar 2024	Q2 FY24Jun 2024	Q3 FY24Sep 2024	Q4 FY24Dec 2024	Q1 FY25Mar 2025	Q2 FY25Jun 2025	Q3 FY25Sep 2025	Q4 FY25Dec 2025	Q1 FY26Mar 2026	Q2 FY26Jun 2026
Revenue	0	0	0	0	0	0	8	0	0	0	0	0
Cost of revenue	0	0	1	0	0	0	0	1	77	1	0	0
Gross profit	0	0	−1	0	0	0	8	−1	−77	−1	0	0
	56	54	58	69	74	77	80	94	19	109	112	123
Research & development	43	41	44	50	57	59	61	75	77	88	89	99
	13	13	14	19	17	18	19	19	19	22	24	24
Selling & marketing	0	0	−1	0	0	0	0	0	0	0	0	0
General & administrative	13	13	15	19	17	18	19	19	19	22	24	24
Other expenses	0	0	0	0	0	0	0	−1	−77	−1	0	0
Operating income	−56	−54	−59	−69	−74	−77	−73	−94	−96	−110	−112	−123
	7	9	12	11	11	8	8	9	6	5	7	12
Interest income	7	9	11	11	10	9	8	7	6	6	7	12
Other non-operating income	0	0	0	0	0	0	0	0	−6	−5	0	−12
Income before tax	−49	−45	−48	−58	−63	−70	−65	−85	−90	−105	−105	−111
Income tax expense	0	0	0	0	0	−4	0	−1	1	1	−3	−1
Net income from continuing operations	−48	−45	−48	−58	−63	−66	−65	−85	−91	−105	−102	−111
Net income	−48	−45	−48	−58	−63	−66	−65	−85	−91	−105	−102	−111
EPS, basic	−$0.73	−$0.64	−$0.62	−$0.75	−$0.81	−$0.84	−$0.83	−$1.07	−$1.15	−$1.31	−$1.17	−$1.11
EPS, diluted	−$0.73	−$0.64	−$0.62	−$0.75	−$0.81	−$0.84	−$0.83	−$1.07	−$1.15	−$1.31	−$1.17	−$1.11
Weighted average shares, basic	66	70	78	78	78	78	79	79	79	79	87	100
Weighted average shares, diluted	66	70	78	78	78	78	79	79	79	79	87	100
EBITDA	−54	−53	−58	−68	−73	−77	−72	−94	−90	−104	−112	−111
Depreciation & amortization	2	1	1	1	1	1	1	1	1	1	1	0
EBIT	−56	−54	−59	−69	−74	−77	−73	−94	−90	−105	−112	−111